ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.06M | -52.73M | -47.68M | -47.22M | -43.26M |
| Total Depreciation and Amortization | 3.21M | 3.15M | 3.05M | 2.98M | 2.95M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.35M | 6.05M | 4.71M | 2.99M | 2.32M |
| Change in Net Operating Assets | -17.66M | -12.30M | -19.50M | -12.58M | -7.76M |
| Cash from Operations | -57.16M | -55.83M | -59.42M | -53.83M | -45.75M |
| Capital Expenditure | -1.34M | -1.12M | -1.16M | -689.70K | -806.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -2.83M | 15.86M |
| Cash from Investing | -1.34M | -1.12M | -1.16M | -3.52M | 15.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.97M | -1.64M | -1.91M | -1.56M | -1.57M |
| Issuance of Common Stock | 49.20M | 2.00K | 69.00K | 71.75M | 71.75M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.93M | -1.90M | -2.08M | 74.76M | 74.79M |
| Foreign Exchange rate Adjustments | 332.10K | -658.00K | -1.49M | -745.70K | -896.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.24M | -59.51M | -64.14M | 16.67M | 43.19M |